<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="120929">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01788371</url>
  </required_header>
  <id_info>
    <org_study_id>2011.6</org_study_id>
    <nct_id>NCT01788371</nct_id>
  </id_info>
  <brief_title>Nucleoside Analogue Prevent Vertical Transmission of Hepatitis B Virus</brief_title>
  <official_title>Nucleoside Analogue in Late Preganancy to Prevent Vertical Transmission of Hepatitis B Virus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hua Zhang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mount Sinai School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Beijing YouAn Hospital</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To explore the antiviral effect of nucleoside analogue in late pregnancy and the safety of
      the antiviral drug to fetus.To establish the best therapy strategy to pregnant women with
      high level of HBV DNA.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Telbivudine and Lamivudine,a preganancy category B medication,reduces HBV DNA and normalizes
      serum ALT in chronic hepatitis B patients with few adverse effects.Two aspects on the drug
      use in pregnancy will be evaluated prospectively in this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>The data on its tolerability and safety in HBeAg+ pregnant woman with HBV DNA&gt;6log10 copies/Ml during late pregnancy and infants</measure>
    <time_frame>perinatal to 28 weeks after infant delivery</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Its efficacy in the reduction of HBV vertical transmission rate</measure>
    <time_frame>perinatal to 28 weeks after infant delivery</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maternal DNA reduction,ALT normalization, and loss/seroconversion of HBeAg or HBsAg</measure>
    <time_frame>perinatal to 28 weeks of postpartum</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">700</enrollment>
  <condition>Hepatitis B Infection</condition>
  <condition>Chronic Infection</condition>
  <condition>Viremia</condition>
  <arm_group>
    <arm_group_label>No antiviral arm</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>provide standard of care to mothers and standard immunoprophylaxis to their infants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lamivudine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>lamivudine treatment from 28 weeks of pregancy to week 4 of postpartum for mothers and standrd immunoprophylaxis to their infants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Telbivudine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Telbivudine treatment from 28 weeks of pregancy to week 4 of postpartum for mothers and standrd immunoprophylaxis to their infants</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telbivudine</intervention_name>
    <description>About 300 mothers with no treatment observedfrom 28 weeks of pregnancy to the week 4 of postpartun</description>
    <arm_group_label>Telbivudine</arm_group_label>
    <other_name>Telbivudine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamivudine</intervention_name>
    <description>About 300 mothers treated with lamivudine or telbivudine from 28 weeks of pregancy to the week 4 of postpartum</description>
    <arm_group_label>Lamivudine</arm_group_label>
    <other_name>lamivudine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        HBeAg+CHB pregnant woman gestational age 28 weeks HBV-DNA&gt;log10 copies/ml

        Exclusion Criteria:

        co-infection with hepatitis A,C,D,E or HIV evidence of hepatocellular carcinoma
        decompensated liver disease or significant co-morbidity concurrent treatment with
        immune-modulators,cytotoxic drugs,or steroids clinical signs of threatened miscarriage in
        early prenancy evidence of fetal deformity by ultrasound examination the biological father
        of the child had CHB
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hua Zhang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing YouAn Hospital</affiliation>
  </overall_official>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 29, 2013</lastchanged_date>
  <firstreceived_date>February 7, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Beijing YouAn Hospital</investigator_affiliation>
    <investigator_full_name>Hua Zhang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Viremia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lamivudine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
